Ingalls & Snyder LLC Makes New $115,000 Investment in Core Laboratories Inc. $CLB

Ingalls & Snyder LLC acquired a new position in shares of Core Laboratories Inc. (NYSE:CLB) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,000 shares of the oil and gas company’s stock, valued at approximately $115,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CLB. Ariel Investments LLC increased its position in shares of Core Laboratories by 7.4% during the first quarter. Ariel Investments LLC now owns 10,342,025 shares of the oil and gas company’s stock valued at $155,027,000 after acquiring an additional 709,455 shares during the last quarter. Hotchkis & Wiley Capital Management LLC acquired a new stake in Core Laboratories in the 1st quarter valued at approximately $6,008,000. Fred Alger Management LLC increased its holdings in Core Laboratories by 32.4% in the 1st quarter. Fred Alger Management LLC now owns 736,853 shares of the oil and gas company’s stock valued at $11,045,000 after purchasing an additional 180,344 shares during the last quarter. Nuveen LLC acquired a new stake in Core Laboratories in the 1st quarter valued at approximately $2,573,000. Finally, Rice Hall James & Associates LLC increased its holdings in Core Laboratories by 71.2% in the 1st quarter. Rice Hall James & Associates LLC now owns 193,798 shares of the oil and gas company’s stock valued at $2,905,000 after purchasing an additional 80,595 shares during the last quarter. 97.81% of the stock is owned by institutional investors and hedge funds.

Core Laboratories Trading Up 0.1%

NYSE:CLB opened at $16.89 on Tuesday. The stock has a 50-day simple moving average of $12.18 and a 200-day simple moving average of $11.85. The stock has a market cap of $786.17 million, a P/E ratio of 25.20, a P/E/G ratio of 9.32 and a beta of 1.38. Core Laboratories Inc. has a 1 year low of $9.72 and a 1 year high of $21.83. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.76 and a current ratio of 2.37.

Core Laboratories (NYSE:CLB) last released its quarterly earnings data on Wednesday, October 22nd. The oil and gas company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.03. The business had revenue of $134.52 million during the quarter, compared to analysts’ expectations of $130.92 million. Core Laboratories had a return on equity of 12.85% and a net margin of 6.21%.The business’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.25 EPS. Core Laboratories has set its Q4 2025 guidance at 0.180-0.22 EPS. As a group, analysts anticipate that Core Laboratories Inc. will post 0.96 earnings per share for the current fiscal year.

Core Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 24th. Stockholders of record on Monday, November 3rd will be issued a $0.01 dividend. The ex-dividend date is Monday, November 3rd. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. Core Laboratories’s dividend payout ratio is presently 5.97%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CLB. Stifel Nicolaus dropped their price objective on Core Laboratories from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, July 16th. Wall Street Zen upgraded shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, July 26th. Zacks Research upgraded shares of Core Laboratories from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Finally, Weiss Ratings raised Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday. Four equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, Core Laboratories presently has an average rating of “Hold” and an average target price of $12.50.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.